IP Library Patent Application 11820747
Patent Application
App. No. 11/820,747

Xanthohumol based protein kinase modulation cancer treatment

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/820,747
Abstract

Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, commonly found in hops.

Claims (8)

1 . A method to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said method comprising administering to the mammal a therapeutically effective amount of a chalcone.

2 . The method of claim 1 , wherein the chalcone is xanthohumol or isoxanthohumol.

3 . The method of claim 1 , wherein the protein kinase modulated is selected from the group consisting of: Abl(T315I), ALK4, Aurora-A, Bmx, BTK, CaMKI, CDK1/cyclinB, CDK2/cyclinA, CDK2/cyclinE, CDK3/cyclinE, CDK5/p35, CDK6/cyclinD3, CDK9/cyclin T1, CHK1, CHK2, CK1(y), CK1γ1, CK1γ2, CK1γ3, CK1δ, cKit(D816H), cSRC, DAPK1, DAPK2, DRAK1, EphA8, EphB1, ErbB4, Fer, Fes, FGFR2, Fgr, Flt4, Fyn, GSK3B, GSK3a, Hck, HIPK2, IKKβ, IRAK1, JAK3, Lyn, MAPK1, MAPKAP-K2, MAPKAP-K3, MINK, MSK1, MSK2, MSSK1, p70S6K, PAK3, PAK5, PAK6, PhKγ2, PI3K, Pim-1, Pim-2, PKA, PKA(b), PKBβ, PKBα, PKBγ, PRAK, PrKX, Rsk1, Rsk2, SGK, SGK2, Syk, TBK1, Tie2, TrkA, TrkB, and TSSK2.

4 . The method of claim 1 , wherein the cancer responsive to kinase modulation is selected from the group consisting of bladder, breast, cervical, colon, lung, lymphoma, melanoma, prostate, thyroid, and uterine cancer.

5 . A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of a chalcone; wherein said therapeutically effective amount modulates a cancer associated protein kinase.

6 . The composition of claim 5 , wherein the chalcone is xanthohumol or isoxanthohumol.

7 . The composition of claim 5 , wherein the composition further comprises a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

8 . The composition of claim 5 , wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2007
From: TRIPP, MATTHEW L.; BABISH, JOHN G.; BLAND, JEFFREY S.; KONDA, VEERA; HALL, AMY J.; PACIORETTY, LINDA M.; DESAI, ANU
To: METAPROTEOMICS, LLC
Reel/Frame 019927/0870 →